Journal of
Clinical Medicine
Article
Computerized Cognitive Rehabilitation Training for
Ugandan Seniors Living with HIV: A Validation Study
AmaraE.Ezeamama1,*,AllaSikorskii1,ParvathyR.Sankar1,NoelineNakasujja2,
MichaelSsonko3 ,NorbertE.Kaminski4,DavidGuwatudde5 ,MichaelJ.Boivin1,6,7
andBrunoGiordani8
1 DepartmentofPsychiatry,CollegeofOsteopathicMedicine,MichiganStateUniversity,
EastLansing,MI48824,USA;sikorska@msu.edu(A.S.);sankarpa@msu.edu(P.R.S.);
boivin@msu.edu(M.J.B.)
2 DepartmentofPsychiatry,MakerereUniversityCollegeofHealthSciences,KampalaP.O.Box7062,Uganda;
drnoeline@yahoo.com
3 MildmayHospital,KampalaP.O.Box24985,Uganda;mikssonko@gmail.com
4 DepartmentofPharmacologyandToxicologyandInstituteforIntegrativeToxicology,
MichiganStateUniversity,EastLansing,MI48824,USA;kamins11@msu.edu
5 DepartmentofEpidemiologyandBiostatistics,SchoolofPublicHealth,MakerereUniversityCollegeof
HealthSciences,KampalaP.O.Box7072,Uganda;dguwatudde@musph.ac.ug
6 DepartmentofNeurology&Ophthalmology,MichiganStateUniversity,EastLansing,MI48824,USA
7 DepartmentofPsychiatry,UniversityofMichigan,AnnArbor,MI48109,USA
8 DepartmentsofPsychiatry,NeurologyandPsychology,SchoolofNursing,UniversityofMichigan,
AnnArbor,MI48109,USA;giordani@umich.edu
* Correspondence: amara.ezeamama@hc.msu.edu;Tel.:+1-517-353-1244
(cid:1)(cid:2)(cid:3)(cid:1)(cid:4)(cid:5)(cid:6)(cid:7)(cid:8)(cid:1)
(cid:1)(cid:2)(cid:3)(cid:4)(cid:5)(cid:6)(cid:7)
Received: 12May2020;Accepted: 23June2020;Published: 7July2020
Abstract:Thefeasibility,acceptabilityandpreliminaryefficacyofcomputerizedcognitiverehabilitation
therapy(CCRT)formitigatingneurocognitivedeclinewasevaluatedinAfricanadults≥50yearsold.
Eighty-oneUgandanswith(n=40)andwithout(n=41)chronichumanimmunodeficiencyviruses
(HIV)wereallocatedCCRT—i.e.,20–45-mincognitivetrainingsessionswithculturallyadaptedvideo
gamesdeliveredviaCaptain’sLogSoftware,orstandardofcare(SOC).Preandpost(i.e.,8-weeks
later)interventionperformancebasedneurocognitivetests,qualityoflife(QOL)andfrailtyrelated
phenotype (FRP) were determined in all respondents. Multivariable linear regression estimated
CCRT-vs. SOC-relateddifferences(β)inneurocognitivebatteries,QOLandFRP.Effectsizes(ES)
forestimatedβwerecalculated. CCRTprotocolwascompletedby92.8%ofpersonsallocatedto
it. RegardlessofHIVstatus,CCRTwasassociatedwithhigherperformanceinlearningteststhan
SOC—interferencelist(β=1.00,95%CI:(0.02,1.98);ES=0.43)anddelayedrecall(β=1.04,95%CI:
(0.06,2.02);ES=0.47). CCRTeffectonverbalfluencywasclinicallyimportant(ES=0.38),butstatistical
significancewasnotreached(β=1.25,95%CI:(−0.09,2.58)). AmongHIV-positiveadults,clinically
importantpost-CCRTimprovementswerenotedforimmediaterecall(ES=0.69),workingmemory
(ES=0.51),verbalfluency(ES=0.51),andtimedgait(ES=−0.44)tasks. AmongHIV-negativeadults,
CCRTresultedinmoderatepost-interventionimprovementinlearningtests(ES=0.45)andlarge
declineinFRP(ES=−0.71),withoutapositiveeffectonsimpleattentionandvisuomotorcoordination
tasks. CCRTinterventionisfeasibleamongolderUgandanadultswithpotentialbenefitforlearning
andverbalfluencytestsregardlessofHIVstatusandloweringFRPinHIV-negativeolderadults.
Keywords: computerizedcognitiverehabilitationtherapy;neurocognitiveimpairment;qualityof
life;frailty;HIV/AIDS;aging
J.Clin.Med.2020,9,2137;doi:10.3390/jcm9072137 www.mdpi.com/journal/jcm
J.Clin.Med.2020,9,2137 2of15
1. Introduction
Demographicandepidemiologictransitionshaveexpandedthepopulationofolderindividuals,[1]
and neurocognitive dysfunction/impairment has become a public health problem worldwide.
Thesetransitionscombinewithforcesofglobalizationandchangesinnutritiontoincreasetherisk
ofnon-communicablediseases(NCDs)[2]suchastypeIIdiabetes,hypertensionandcardiovascular
diseases [3] in many Sub-Saharan African countries. In Uganda, the rise in NCD in the general
population has been characterized as severe [4]. NCDs are often accompanied by metabolic
dysregulationsandfrailty,i.e.,vulnerabilityduetodeclineinfunctionacrossmultiplephysiologic
systems,whichconstituteindependentriskfactorsforage-relatedneurocognitivedysfunction,disability
andlowqualityoflife(QOL)[4–7].
Age-related changes are seen in executive activities involving working memory, attention,
taskswitching, andmotorresponsespeed[8]. Thesecognitive/behavioralchangeswithagingare
matched with neuroanatomical changes, including reduced volume of gray matter in the brain;
progressive thinning out of the cerebral cortex, particularly in the frontal lobes; lower levels of
dopamine and serotonin neurotransmitters; and lower binding potential of neurotransmitters to
respectivereceptors[8]. Olderadultslivingwithhumanimmunodeficiencyviruses(HIV)infectionare
atespeciallyhighriskofprematureneurocognitivedecline,frailtyandlowQOL.AgingandNCD-related
riskfactorssynergizewithvirus-mediatedneuroinflammation[9]andHIV-treatment-relatedside-effects
suchheartdisease[10]toadvancethetimetoonsetofvariousaspectsofaging-relatedneurocognitive
dysfunction,frailtyandlowQOL[11]. Onefunctionalconsequenceoftheseoutcomesisthatcomplex
tasks, such as cooking, are the first areas affected, followed by the ability to execute instrumental
activitiesofdailyliving,asneurocognitivedeclineandfrailtyworsen[11].
There are no known effective treatments to mitigate aging or HIV-associated premature
neurocognitivedecline. However,ithasbeenshownthatwhenthebrainisexposedtochallenging
andstimulatingtasks,itwillgrow(likeneurogenesisinhippocampus),whiledeprivationresultsin
shrinkageofthebrainregardlessofage[12]. Hence,tasksthatincorporateelementsofnewnessand
challengehavethepotentialtomaintainorimproveneurocognitiveperformanceandincreaseQOL
invulnerablepopulations[12]. Recentresearchsuggeststhatcognitivestimulationprogramsinthe
formofdifferentactivitiesthataregearedtowardsmemory,attention,gnosis,andexecutivefunctions,
whencompletedfor24weeksbyHIVaffectedindividuals,resultinbetterneuropsychologicaltest
performance,evenwhenadjustedforage,gender,education,andrace[10]. Ourgroup[13,14]and
others[10,15–17]haveadaptedCCRTprogramsforcomputerdeliveryintheformofsimplegame-like
programsthatcanbeusedbylayindividualsonalaptoportabletwithminimaltraining. Thispotential
utilityofcomputerizedcognitiverehabilitationtherapy(CCRT)forimprovingaspectsofneurocognitive
functionrecentlyhasbeendemonstratedforAfricanchildrenwithcerebralmalaria[18–21]andin
severalWesternstudies,includingolderadultsenrolledinthemulti-centertrial,AdvancedCognitive
Training for Independent and Vital Elderly (ACTIVE) trial [22], adults with heart disease [23,24],
andadultssubjectedtoprolongedbed-rest[13,14]. However, thefeasibilityofCCRTintervention
formitigatingagingandHIV-associatedneurocognitivedeclineintheAfricansettingisunknown.
Hence,inthisstudy,weevaluatedfeasibilityofaculturallyadaptedCCRTinterventionamongolder
UgandanswithandwithoutHIV-infection. Further,thisstudyassessesthepreliminaryefficacyofa
CCRTinterventionviaeffectsizesforimprovementinneurocognitiveoutcomes(primaryoutcome),
QOLandreductioninfrailty-relatedphenotype(secondaryoutcomes)amongolderadultswithand
withoutchronicHIVinfection. WefurtherexplorethevariationsinCCRTfeasibilityandbenefitby
HIVstatus.
J.Clin.Med.2020,9,2137 3of15
2. ExperimentalSection
2.1. StudyDesign
Thisisanon-randomizedtrialofCCRTvs. standardofcare(SOC,i.e.,noCCRT)inolderHIV-positive
patientsconnectedtoHIVcareatMildmayUgandaHospitalandHIV-negativecommunitycontrols
whowerematchedtoHIV-positiveadultsbyage(±5years),sexandvillageofresidence. Consenting
eligibleparticipantswereallocatedonafirst-come-first-servedbasistoCCRTinterventionorSOCin
alternatingblocksofeightparticipantsofsameHIVstatustilltargetsamplesizewasattained.
2.2. Setting
ThefeasibilitytrialwasconductedatMildmayUgandaHospital—atertiarycomprehensivehealth
centerthatprovidescareandtreatmentforHIV-infectedpersonsasitsprimaryfunction. Atthetimeof
studyinitiation,MildmayClinicprovidedcareforanestimated15,300HIV-infectedadults,ofwhom
15,200wereoncombinationantiretroviraltherapy(ART).
2.3. RecruitmentandEnrolmentProcess
ParticipantswereenrolledbetweenJuly2017andApril2018. HIV-infectedadultswererecruited
fromthestudyhospitalandmatchedtoHIV-negativecommunitycontrolsbyage,sexandvillageof
residence. Duetostaffingandspaceconstraintscombinedwiththeneedtopreserveconfidentiallyof
HIV-positiveindividuals,allocationtocognitivetrainingwasdoneinblocksbyHIVstatus. Amaximum
ofeightindividualscouldbecognitivelytrainedatanyonetime. Hence,thefirst16individualswere
identifiedandthefirsteightthatconsentedtomultiplestudyvisitsforthepurposeofimplementingthe
CCRTprotocolwereallocatedtoCCRTarm. TheremainingeightindividualswereallocatedtoSOC
arm. ThesecondblockofenrolleesweredemographicallymatchedHIV-negativecontrolsallocatedto
eitherCCRTorSOCinthesamemannerasdescribedforHIV-positiveadults.
2.4. EligibilityandExclusionCriteria
Eligibilitycriteriaincluded: (a)menorwomenaged≥50yearsold,(b)ifHIV+mustbeconnected
toHIVcareattheMildmayUgandaHospital,(c)mustresidewithin25kmofthehospital,and(d)if
HIV-negative,mustconsenttoHIV-testingatenrolment. Allparticipantsprovidedwritteninformed
consentforstudyparticipationandwerewillingtoreturnforimplementationoftheCCRTprotocol
if allocated CCRT. Subjects who were very ill or physically disabled and thus unable to undergo
performance-basedassessmentswereexcluded.
2.5. InterventionAllocationandStandardofCare(SOC)
ParticipantsintheCCRTinterventionarmreceived20–45-minsessionsofcognitivetrainingon
laptopcomputerswithculturallyadaptedvideogamesthroughCaptain’sLogSoftwaredelivered
2daysperweek(twotrainingsessionsperday)overaminimumof5weeks. Allparticipantswore
sound-deadeningheadphonesandsatfarenoughapartfromoneanothertoavoidbeingdistracted
byotherparticipantstrainingatthesametime. Researchassistantsproficientinthelocallanguage,
Luganda,supervisedCCRTandprovidedinstructionsorguidanceasneeded. CCRTintervention
consistedoftwocomponents—culturallyadaptedBrainPoweredGames—Uganda(BPG-U,20min)
and Spatial Navigation Training (SNT, 25 min). Participants in the SOC arm were not cognitively
trained,buthadneuropsychological,QOLandfrailtytestsonthesamescheduleastheCCRTgroup.
Atalltimesduringthistrial,HIV-positiveparticipantscontinuedtoreceivestandardmedical
careaccordingtoUganda’sMinistryofHealth(MoH)guidelines. Inbrief,HIV-positiveadultsare
initiallyassignedtothefirstlinethreedrugcombinationhighlyactiveantiretroviraltherapy. Typically,
thefirstlinecocktailincludes: Abacavirorzidovudine(AZT)ortenofovir(TDF)+lamivudine(3TC)+
efavirenz(EFV)ornevirapine(NVP).Incaseoftreatmentfailureordrugtoxicity,patientsthatwereon
J.Clin.Med.2020,9,2137 4of15
abacavirorTDFareassignedtoAZT+3TCplusaproteaseinhibitorwhichcouldbeAtazanaviror
lopinaviarboostedwithritonavir. AllHIV+personsaremaintainedoncotrimoxazoleprophylaxisor
dapsoneforlifeandstronglyencouragedtoconsistentlysleepunderinsecticide-treatedmosquitonets
tolimittheriskofmalaria. IntheabsenceofasystemofpreventiveprimaryhealthcareinUganda,
most“healthy”HIV-negativeindividualsarenotconnectedtoroutinecareunlesstheyareill. Thus,
usualstudy-relatedmedicalcareforHIV-negativeparticipantsincludedreferraltothenationalreferral
hospitalforfurthermanagementincasetheydevelopclinicalsigns/symptoms. Thisisconsistentwith
thestandardpracticeintheUgandahealthsystem.
2.6. Measurements
Atbaselineonly,weadministeredadetailedbackgroundinformationquestionnairetoobtainsocio-
demographicdata,includingage,parity,education,residence,employmentstatus,socio-economic
status variables, marital status, and past/current use of tobacco, alcohol, and other substances.
TheCenterforEpidemiologicalStudies-Depressionscalewasusedtoassessdepressivesymptoms[25].
Psychosocialadversitywasmeasuredasacute(within30days),recent(within5years)andasalifetime
cumulativeadversity,usingtheperceivedstressscaleandrecentandlifetimeadversityquestionnaires
adaptedandtranslatedforthestudysetting[26]. Bloodsampleswerecollectedfromeachparticipant
atenrollmenttomeasureCD4counts,completebloodcounts(CBCs),bilirubin,creatinine,andalanine
transferase, as part of clinical standard of care for all patients. In addition, lipids profile testing
(highdensitylipoproteins(HDL),lowdensitylipoproteins(LDL)andtriglycerides)wasdoneper
standardprotocol.
2.7. StudyOutcomes
Feasibility of the CCRT intervention was assessed by (a) percent of participants completing
CCRTsessionsamongthoseallocatedintheinterventionand(b)percentofthoseallocatedCCRTthat
completedthestudyprotocolinatimelymanner(8weeks). Preliminaryefficacywasassessedwith
respectto(a)performance-basedneurocognitivetests(primaryoutcome),(b)QOLandfrailty-related
phenotype(FRP)(secondaryoutcomes). Outcomemeasuresdescribedbelowwereevaluatedtwice—at
study enrollment and again at week 6 following CCRT training or equivalent time period for the
SOCgroup.
2.7.1. Feasibility/Acceptability
Feasibility/acceptabilityofinterventionwasprimarilyevaluatedasoverallandHIV-statusspecific
rateofstudyprotocolcompletion(i.e.,pre-interventionneuropsychologicaltest,20CCRTsessions
andpost-interventionneuropsychologicaltesting). Asecondmeasureoffeasibility,timelycompletion,
isdefinedtoestimatenumberofadultparticipantsthatcompletedthestudyprotocolwithin8weeks
ofenrolment.
2.7.2. CognitivePerformance
Cognitiveperformancewasassessedbyperformanceonasetofstandardizedpaper-and-pencil
tests previously shown to be culturally-independent and sensitive for detecting HIV-associated
neurocognitivedisorder(HAND)andHIVdementia(HAD)inHIV+patientsinUgandabymembers
ofourteam[27]. AllthetestshavehadtheirinstructionsandcontenttranslatedintoLuganda—thelocal
language,whichwasusedtopresentalltestmeasures. Testswerescoredaccordingtomanufacturer’s
instructionsandwereanalyzedascontinuousoutcomevariables. Thecognitiveassessmentbattery
includednineseparatetestscoveringseveralcognitivedomains,asdescribedbelow:
(a) Gross motor function—evaluated using Timed Gait test time to quantify amount of time
(inseconds)takentocompletewalkinga10-yarddistanceandback.
J.Clin.Med.2020,9,2137 5of15
(b) Finemotorfunction—evaluatedusingtwotests: (i)FingerTapping(numberoftapswithin10s)
and(ii)theGroovedPegboardTest,whichmeasurestheamountoftime(inseconds)ittakesto
place25slottedpegsintorowsofrandomlypositionedslotsonaboard.
(c) Executivefunction—measuredusingColorTrails2test(timetocompletionofacomplextask
requiring attention to two aspects of problem solving simultaneously) and verbal (semantic)
fluency(numbercorrectanimalsnamedwithin60s)toquantifyproficiencyincompletingtasks
thatrequireplanning,organizing,prioritizing,focus/attention,multi-tasking,andinhibitionof
irrationalimpulses.
(d) Speed of Processing—measures how long it takes individuals to complete a cognitive visual
scanningandsimplesequencingtaskusingColorTrails1(time(inseconds)totaskcompletion)
andDigitSymboltestinwhichparticipantsareaskedtodrawinsmallsymbolsinspacesunder
numbers corresponding to number/symbol pairs at the top of the test sheet (number correct
matcheswithin90s).
(e) Attention/Short-termworkingmemory—measuredasnumbercorrectonDigitSpanForward
andDigitSpanBackwardtests.
(f) VerbalLearning/Memory—measuresabilityofindividualstoacquireandretrievecomponentsof
memoryusingtheWHO-UCLAAuditoryVerbalLearningTest.
2.7.3. QualityofLife
QOLwasmeasuredusingtheshortformMedicalOutcomesStudyquestionnaire. Individualscores
forgeneralhealthperceptions,physicalfunctioning,pain,vitality,rolefunctioning,socialfunctioning,
andmentalhealthwerecomputed. AnoverallQOLscorewasderivedbysummingthesecomponents
andscalingtotalscoretoatheoreticalmaximumof100.
2.7.4. FrailtyRelatedPhenotype
FRPisaclinicalstateofincreasedvulnerabilityresultingfromagingassociateddeclineinmultiple
physiologicsystems. ItwasdefinedusingtheEdmontonfrailscaletomeasurefunctionalvulnerability
inthefollowingdomains: cognition,generalhealthstatus,functionalindependence,medicationuse,
continence,functionalperformance,socialsupport,andunintentionalweightloss. AnoverallFRP
scoreisthesumofrespectivedomainsandanalyzedasacontinuousoutcomevariable.
2.8. StatisticalIssues
Statisticalpower: Inlightofthefeasibilitypilotnatureofthisinterventionandabsenceofformal
apriorihypotheses,specificpowercalculationwasnotapplicable. Estimatesoftheeffectsizesfrom
thepresentstudywillinformpoweranalysesforfuturemoredefinitiveinvestigation.
StatisticalAnalysis: DescriptiveanalysesbyinterventionarmandHIVstatussummarizedthe
distributionsofoutcomesandpotentialcovariates. ToassessfeasibilityofCCRTintervention,therates
ofprotocolcompletionoverallandaccordingtoHIVstatusweredetermined. Multivariablegeneral
linearmodelswereusedtoestimateCCRTvs. SOC-relateddifferences(βcoefficients)inneurocognitive
batteries,QOL,andFRP.Thedependentvariablesinthesemodelswereprimary/secondaryoutcome
measuresatweek8(oneatatime),andcovariatesincludedbaselineversionoftheoutcome,number
ofnon-HIVcomorbidconditions,age,sex,levelofeducation,interventiongroup(CCRTvs. SOC),
and HIV status. The coefficients for the intervention group variable (β) and their 95% confidence
intervals(CIs)providedestimatesoftheinterventioneffects. Inaddition,effectsizeswerecalculated
asdifferencesbetweengroupmeansintheadjustedstandarddeviationunits(squarerootofthemean
squarederror)toquantifyclinicalrelevanceofestimatedβsandinformplanningoffuturestudies.
Effectsizesof0.5oralargerareubiquitouslyuniversalfordefinitionofclinicalimportance,[28]and
effectsizesof0.33orgreaterareoftendeemedclinicallyimportantaswell[29]. Allanalyseswere
implementedinSASv.9.4. ToexploredifferencesinCCRTeffectsaccordingtoHIVstatus;intervention
J.Clin.Med.2020,9,2137 6of15
group by HIV status interaction was added to the models; and estimates of the CCRT effects (β’s,
95%CIs,effectsizes)wereobtainedbyHIVstatus.
2.9. EthicalApproval
ThisprojectwasethicallyreviewedandapprovedbytheinstitutionalreviewboardsofMichigan
StateUniversity,(Protocol#17-205)andMakerereUniversityResearchEthicsCommittee(MUREC,
protocol#: RECREF0403-2017). Inadditiontotheseapprovals, theimplementationofthisstudy
protocolwasfurtherapprovedbytheUgandaNationalCouncilforScienceandTechnology(Permit#:
HS2275).
3. Results
3.1. DescriptionofEnrolledParticipants
MaleandfemaleUgandansbetween50and87yearsofagewereenrolled. Thesampleincluded
54.6%female(n=44)andbydesignequalnumberofHIV-infected(n=40,meanage=57.9(SD(standard
deviation)=7)years)andage(±5years),sexandvillageofresidence-matchedHIV-negativecommunity
controls(n=40,meanage=61.8(SD=7)years). AllHIV+adultscurrentlyreceivedprimaryhealth
careatMildmayHospital. ParticipantsallocatedCCRTvs. SOChadsimilardistributionsofmatching
factors(age,sex,villageofresidence),aswellyearsofeducation,prevalenceofnon-HIVcomorbid
diseases,durationofHIVdisease,psychosocialstress,immunefactors,andbaselineperformanceinall
neuropsychologicaltestbatteries(Table1).
Table 1. HIV-infected and demographically matched HIV-negative community dwelling adults
50–87yearsoldfromtheWakisoDistrictofUgandanon-randomlyallocatedCCRTvs. NoCCRTfor
evaluationofinterventionfeasibility.
CCRT,n=41 NoCCRT,n=40 p-Value
Age(years) 59.7(8.2) 60.0(6.6) 0.894
n(%) n(%)
FemaleSex 24(58.5) 20(50.0) 0.441
HIVStatus
HIV+ 19(47.5) 20(50.0) 0.823
Mean(SD)YearsonHAART(ifHIV+) 8.8(5.6) 9.7(3.8) 0.564
YearsofEducation
≤Primary 21(55.3) 17(44.7) 0.539
Some/CompletedOrdinaryLevels 10(26.3) 14(36.8)
SomeAdvancedLevelsorHigher 6(15.8) 6(15.8)
Numberofnon-HIVcomorbiddiagnoses
0 11(27.5) 13(33.3)
1 18(45.0) 16(41.0)
0.838
2 6(15.0) 7(18.0)
3+ 5(12.5) 3(7.7)
LipidProfileTests Mean(SD) Mean(SD)
HighCholesterol 16(40.0) 14(35.0) 0.559
LowHDL 16(40.0) 14(35.0) 0.559
HighLDL 19(47.5) 15(37.5) 0.534
HighTriglycerides 10(25.0) 8(20.0) 0.556
HighCRP 2(5.0) 7(17.5) 0.127
CESDScore 16.7(11.0) 16.1(9.5) 0.816
FrailtyScore 3.1(1.9) 2.7(1.5) 0.273
QualityofLifeScore 72.1(11.1) 71.0(9.4) 0.621
BodyMassIndex 24.4(4.7) 23.6(6.0) 0.562
Hemoglobin 14.3(2.4) 14.2(1.9) 0.746
StressScores mean(SD) mean(SD)
AcuteStress 20.5(6.2) 18.9(7.0) 0.311
RecentLifeStress(within5years) 11.8(5.6) 11.3(4.9) 0.678
NumberofLifetimeAdversity 5.5(3.8) 5.6(3.3) 0.963
ImmuneMeasures n=34,mean(SD) n=34,mean(SD)
AbsoluteCD4cellcount 612.8(323) 663(320) 0.516
CD4/CD8Ratio 1.2(0.6) 1.3(0.9) 0.418
J.Clin.Med.2020,9,2137 7of15
Table1. Cont.
CCRT,n=41 NoCCRT,n=40 p-Value
NeuropsychologicalTestBattery Mean(SD) Mean(SD)
1.TimedGait(time,s) 12.8(7.6) 12.4(4.2) 0.819
2.VerbalFluency(TotalCorrect) 12.5(2.9) 12.3(3.4) 0.779
3.SymbolDigitModality(numbercorrect) 23.3(12.3) 22.8(11.7) 0.868
4.FingerTapping(numberoftaps) 32.9(7.4) 33.6(9.3) 0.707
5.Overall(Forward+Backward) 8.5(3.3) 7.3(2.8) 0.108
6.ColorTrails[100×(T2−T1)/t1] 52.5(54.4) 51.8(46.6) 0.949
7.GroovedPegboardTest(time,s)
Non-DominantHand 150.9(55.7) 146.0(49.7) 0.677
DominantHand 123.2(47.8) 119.5(48.3) 0.739
8.WHOUCLAVerbalLearningTest(numbercorrect)
SumofImmediateRecalls(Trials1–5) 8.4(1.7) 7.9(1.8) 0.291
InterferenceListRecall(Trial6) 5.0(1.9) 4.6(2.2) 0.335
PostInterferenceListRecall(Trial7) 8.0(2.5) 7.7(2.5) 0.563
DelayedRecallofFirstlist(Trial8) 7.8(2.6) 7.9(2.7) 0.864
DelayedRecall&Recognition(Trial9) 12.9(2.1) 12.6(2.7) 0.530
CRP=C-reactiveprotein,CCRT=computerizedcognitiverehabilitationtherapy,HIV=humanimmunodeficiency
virus,HDL=highdensitylipoprotein,LDL=lowdensitylipoprotein,SD=standarddeviation,CD=cluster
ofdifferentiation.
ThemediandurationoncARTamongHIV+adultswas10yearswitharangeof1to18years.
MeanCD4cellcountwas564(SD=319)cellspermicroliter,and57.5%(n=23)werevirologically
suppressed. Lipidprofiletests,educationallevelandprevalenceofnon-HIVcomorbidconditions
weresimilaracrossHIVgroups. AverageperformanceonWHOUCLAlearningtestsweresimilar
across HIV groups. However, average performance in finger tapping, timed gait, score digit and
grooved pegboard tests were higher for HIV-negative community controls relative to HIV+ older
Ugandans(Table2).
Table2. HIV-infectedanddemographicallymatchedHIV-negativecommunitydwellingadults50–87
yearsoldfromtheWakisoDistrictofUgandanon-randomlyallocatedCCRTvs.NoCCRTforevaluation
ofinterventionfeasibility.
HIV+,n=40 HIV−,n=41 p-Value
Age(years) 58.1(7.3) 61.6(7.3) 0.033
n(%) n(%)
FemaleSex 24(58.5) 20(50.0) 0.823
median(range)YearsonHAART(ifHIV+) 10(1to18) n/a
YearsofEducation
≤Primary 21(55.3) 21(52.5) 0.501
Some/CompletedO’Levels 10(26.3) 14(35.0)
SomeA-LevelsorHigher 8(20) 5(12.5)
Numberofnon-HIVcomorbiddiagnoses 1.05(1.5) 1.15(1.6) 0.658
LipidProfileTests Mean(SD) Mean(SD)
Cholesterol 5.0(1.13) 4.90(0.99)
HDL 1.40(0.40) 1.40(0.50) 0.929
LDL 2.92(1.01) 3.12(1.04) 0.403
Triglycerides 1.66(1.3) 1.35(0.46) 0.192
CRP 6562(16464) 3310(5068) 0.267
CESDScore 15.1(11.5) 17.7(8.8) 0.430
FrailtyScore 3.1(1.9) 2.9(1.5) 0.501
QualityofLifeScore 74(11.0) 69.0(9.3) 0.045
BodyMassIndex 23.5(5.1) 24.6(5.7) 0.379
Hemoglobin 13.8(1.6) 14.8(2.5) 0.0376
StressScores Mean(SD) Mean(SD)
AcuteStress 18.1(6.4) 21.2(6.6) 0.039
RecentLifeStress(within5years) 11.7(6.2) 11.3(4.1) 0.794
NumberofLifetimeAdversity 5.5(3.6) 5.6(3.6) 0.963
ImmuneMeasures n=34, n=34,
Mean(SD) Mean(SD)
AbsoluteCD4cellcount 564(319) 722(304) 0.042
CD4/CD8Ratio 0.85(0.38) 1.75(0.80) <0.001
NeuropsychologicalTestBattery Mean(SD) Mean(SD)
J.Clin.Med.2020,9,2137 8of15
Table2. Cont.
J. Clin. Med. 2020, 9, x FOR PEER REVIEW 8 of 16
HIV+,n=40 HIV−,n=41 p-Value
3. Symbol Di1g.itT iMmoeddaGliatiyt ((tnimuem,sb)er correct) 22.81 3(1.91(.76.)8 ) 23.21 1(.142(.34.)3 ) 0.08.06775
4. Fi2n.gVeerr TbaalpFpluinegn c(ynu(TmotbalerC oorfr teacpt)s) 30.71 2(.92.(23).1 ) 35.172 .(96.(32).5 ) 0.00.30655
5a.3 S.cSoyrmeb doilgDiti gfoitrMwoadrdal i(tsyim(npulme baetrtecnotriroenct)) 3.272 (.18.(81)1 .6) 4.253 (.21.(91)2 .4) 0.00.85647
5b. Score dig4i.t FbinacgkerwTaarpdp i(nsgho(nrtu mtebrmer ovfetrabpasl) memory) 3.43 0(1.7.4(9) .2) 4.13 5(.17.9(6). 3) 0.00.06045
5a.Scoredigitforward(simpleattention) 3.7(1.8) 4.5(1.9) 0.054
5. Overall (Forward + Backward) 7.1 (2.9) 8.6 (3.2) 0.034
5b.Scoredigitbackward(shorttermverbalmemory) 3.4(1.4) 4.1(1.9) 0.064
6. C 5.o Olo vr
e
T rar la li (l Fs o[ r1 w00
a
r×
d
(+T2
B
a−
c
kT w1) a/ rt d1 )] 107.3
7
.( 16 (8 2. .5 9)
)
84. 80
.
6(5 (6 3.)
2 )
0. 01 .00 30
4
7. G6r.oCoovleodrT Praeiglsb[o1a0r0d× T(eTs2t −(tiTm1)e/t,1 s]) 107 .3(68.5) 84 .0(56) 0. 100
7.GNrooonv-eDdoPmegibnoaanrtd HTeasntd(t ime,s) 0.17 (1.04) −0.17 (0.94) 0.128
NDoonm-Dinoamnitn HanatnHda nd 0.201.1 (71(.11.)0 4) −0.− 201. 1(70.(805.9) 4) 0.00.16208
DominantHand 0.21(1.1) −0.21(0.85) 0.060
8. WHO UCLA Verbal Learning Test (Number Correct)
8.WHOUCLAVerbalLearningTest(NumberCorrect)
Sum of Immediate Recalls (Trials 1–5) 8.0 (1.7) 8.3 (2.5) 0.438
SumofImmediateRecalls(Trials1–5) 8.0(1.7) 8.3(2.5) 0.438
InteInrtfeerrfeenrecnec LeiLsits RtReceacalll l((TTrriiaall 66)) 5.05 (.10.(91). 9) 5.05 (.01.(71).7 ) 0.04.43388
PosPt oIsnttIenrtfeerrfeenrecnec eLiLsits tRReeccaallll ((TTrriiaall 77)) 7.47 (.24.(32). 3) 8.18 .(12.(42).4 ) 0.01.15588
DelDaeyleady eRdeRceaclla lolfo FfiFrisrts tlilsistt ((TTrriiaall 88)) 7.57 (.25.(42). 4) 8.38 .(32.(42).4 ) 0.01.19988
DelayedRecall&Recognition(Trial9) 12.7(2.4) 12.9(2.5) 0.689
Delayed Recall & Recognition (Trial 9) 12.7 (2.4) 12.9 (2.5) 0.689
CRP= CCR-Pr e=a cCtiv-reepacrotitveein p,CroCtReiTn,= CcComRTpu =te rciozmedpcuotgerniizteivde creohganbitiliivtaet iroenhathbeilriatpatyi,oHn IVth= erhapuym, aHnIiVm m= uhnuomdeafinc iency
virus,HDL=highdensitylipoprotein,LDL=lowdensitylipoprotein,SD=standarddeviation,CD=cluster
ofdiffi em rem nu tin ato iod nef .iciency virus, HDL = high density lipoprotein, LDL = low density lipoprotein, SD =
standard deviation, CD=cluster of differentiation.
3.2. Feasibility/AcceptabilityofCCRT
3.2. Feasibility/Acceptability of CCRT
OfthOef4 t1hien 4d1i vinidduivaildsuinalist iianliltyiaalllylo aclalotecdatCedC CRCTR,3T8, (3982 (.982%.8)%co) mcopmleptleedtedth tehset ustduydyp rportootococollw witihth2 277( 71%)
doing(7s1o%w) ditohining 8sow weiethkisn. 8A wmeoeknsg. Athmeo2n1gH thIeV 2+ 1 aHdIVul+t sadaulllotsc aatlleodcaCteCdR CTC,R19T,( 1990 .(59%0.5)%co) mcopmleptleetdedth tehes tudy
protosctould(yF pigroutroeco1l) .(FMigeuarne 1a)n. dMmeaend ainand mtimedeiatno tciomme ptol ectoiomnpoleftiConC RofT CiCnRteTr vinetnetrivoenntaiomno anmgoHngIV H-iInVf-ected
adultisnwfeectreed7 .a9d(uSlDts =w2e.r9e) a7.n9d (S6D.0 (=r a2n.9g) ea:n4d.6 6t.o0 1(r2a.1n)gwe: e4e.k6 store 1s2p.e1c) twiveeelkysw rietshp1ec1t(iv5e7l.y9 %w)itcho m11p (l5e7ti.9n%g)s tudy
completing study protocol within 8 weeks of initial neuropsychological assessment. Among 20
protocolwithin8weeksofinitialneuropsychologicalassessment. Among20demographically-matched
demographically-matched HIV-negative adults allocated CCRT, all completed the study protocol
HIV-negativeadultsallocatedCCRT,allcompletedthestudyprotocolwith17(85%)ofcompletions
with 17 (85%) of completions within 8 weeks. The mean and median times to completion of CCRT
within8weeks. ThemeanandmediantimestocompletionofCCRTinterventionamongcommunity
intervention among community controls were 6.4 (SD = 2.4) and 5.3 (range: 4.0 to 11.7) weeks
controlswere6.4(SD=2.4)and5.3(range: 4.0to11.7)weeksrespectively.
respectively.
FigurFeig1u.rSea m1. pSlaemseplleec tsieolnecttoioenv atolu aevtealtuhaetefe athseib ifleiatysibainlidtyp raenldim pirnealirmyiinmaprya citmopfaCcot mofp uCtoemripzuedterCizoegdn itive
RehaCboilgitnaittiivoen RTerhaainbiilnitgatoionnP Terrafionrinmga onnc ePeBrafosermdaNnceeu Broacseodg nNiteiuvreocFougnncittiivoen F,uQnuctailointy, QoufaLliitfye aonf dLifFer ailty
amonagndU Fgraaniltdya anmAondgu Ultsga5n0dyaena Arsdualntsd 5a0b yoevares, aJnudly ab2o0v1e7,– JOulcyt o20b1e7r–2O0c1to8b.eCr C20R1T8,. CcoCmRTp,u ctoemripzuetderciozegdn itive
rehabcioligtnaittiiovne rtehhearbaipliyta.tion therapy.
J.Clin.Med.2020,9,2137 9of15
OverallSample: EffectofCCRTonneurocognitiveperformance,QOLandfrailty
Adjustedforbaselinevalueofrespectiveoutcomes,non-HIVcomorbiddisease,HIVstatus,age,
sex,andeducationalattainment;olderadultsthatreceivedCCRThadhigheraveragepost-intervention
scoresofclinicalimportanceintestsverbalfluency(β=1.25,95%CI:−0.09to2.58,ES=0.38);andthe
following subscales of the WHO UCLA tests of learning: interference list recall (β = 1.00, 95% CI:
0.02–1.98;ES=0.43)anddelayedrecall(β=1.04,95%CI:0.06–2.02;ES=0.47)relativetopeersallocated
noCCRTintervention. However,timetocompletionofmotorspeed/hand-eyecoordinationtaskswas
modestlyelevatedforparticipantsthatreceivedCCRTvs. noCCRT(groovedpeg-boarddominant
hand: β=0.21,95%CI:−0.07,0.50;ES=0.32). AllotherCCRT-relateddifferencesinneurocognitive
outcomeswerestatisticallyinsignificantandofonlysmallormodestclinicalsignificance. Therewas
no association between CCRT and post-intervention quality of life (β = −2.64, 95%CI: −6.7 to 1.4;
ES=−0.28)andfrailty-relatedphenotype(β=−0.12,95%CI:−0.74to0.50;ES=−0.09)(Table3).
3.3. EffectofCCRTonNeurocognitivePerformance,QOLandFrailtyaccordingtoHIVStatus
AmongHIV+olderadults,CCRTinterventionresultedinpost-interventionscoreimprovement
oflargeclinicalimportanceintheareasofimmediaterecall(β=0.91,95%CI:0.08–1.73;ES=0.69),
digitspanbackwards(β=0.79,95%CI:−0.18–1.77;ES=0.51)andverbalfluency(β=1.68,95%CI:
−0.32–3.67;ES=0.51). AlsoamongHIV+olderadults,thereceiptofCCRTinterventionresultedin
higherscoresofclinicalimportanceinpost-interventiondelayedrecall(ES:0.41to0.44,p=0.168to
0.202)andfingertapping(ES=0.38,p=0.233)testsaswellasfastertimetocompletionofcolortrails
(ES=−0.32,p=0.306)andtimedgait(ES=−0.44,p=0.167)tasks.
AmongHIV-negativedemographically-matchedcontrols,CCRTinterventionontheonehand
resultedinFRPdeclinesoflargeclinicalimportance(β=−0.54,95%CI:−1.00to−0.08;ES=−0.71)
andimprovementinWHOUCLAlearningtestsforsubscalesofinterference(ES=0.45,p=0.129)
anddelayedrecall(ES=0.45,p=0.135)ofclinicalimportance. Ontheotherhand,receiptofCCRT
interventionwasassociatedwithlowerperformanceindigitspanforwardtest(ES=−0.44,p=0.147)
andlongertimetocompletionofgroovedpegboardtask(ES=0.41,p=0.172)amongHIVnegative
communitycontrolsthatreceivedCCRTvs. nointervention(Table4).
Table3. Age,sex,HIVstatus,andeducation-adjustedeffectofCCRTvs. noCCRTinterventionon
performanceinrespectiveNeurocognitiveTestBatteries.
LSMeans(SE)
β(95%CI) EffectSize p-Value Adj.R2
CCRT NoCCRT
WHOUCLALearningTests(#Correct)
ImmediateRecall(trials1–5) 9.94(0.20) 9.60(0.20) 0.33(−0.29,0.86) 0.25 0.243 0.46
InterferenceListRecall(trial6) 5.44(0.28) 5.72(0.27) −0.28(−1.02,0.46) −0.16 0.407 0.25
PostInterferenceListRecall(trial7) 10.1(0.35) 9.1(0.35) 1.00(0.02,1.98) 0.43 0.046 0.30
DelayedRecall(trial8) 10.2(0.36) 9.2(0.35) 1.04(0.06,2.02) 0.47 0.038 0.41
WordRecognition(trial9) 13.7(0.32) 13.6(0.32) 0.09(−0.50,0.99) 0.04 0.841 0.12
DigitSpanTest(#correct)
Shorttermauditorymemory/simpleattention 4.5(0.19) 4.8(0.19) −0.36(−0.88,0.17) −0.29 0.186 0.34
Short-termverbalmemory 4.4(0.24) 4.01(0.25) 0.45(−0.21,1.12) 0.29 0.116 0.18
Overallscore 8.76(0.35) 8.72(0.34) 0.03(−0.91,0.97) 0.01 0.949 0.34
ColorTrails(time,s) 99.5(9.7) 112.9(9.7) −13.4(−39.8,14.0) −0.21 0.327 0.05
FingerTappingTest(time,s) 38.1(0.85) 37.3(0.87) 0.83(−1.6,3.2) 0.15 0.498 0.05
GroovedPegBoard(time,s)
GroovedPegboardNDH 0.06(0.11) −0.12(0.12) 0.18(−0.16,0.51) 0.24 0.296 0.45
GroovedPegboardDH 0.07(0.10) −0.14(0.11) 0.21(−0.07,0.50) 0.32 0.143 0.51
VerbalFluency
VerbalFluency(Tot.Correct) 13.4(0.85) 12.2(0.91) 1.25(−0.09,2.58) 0.38 0.068 0.21
TimedGait(time,s) 11.4(0.52) 12.1(0.52) −0.65(−2.1,0.83) −0.20 0.401 0.15
SymbolDigitModality(#correct) 24.5(1.9) 26.32.0) −1.78(−4.74,1.19) −0.25 0.239 0.63
Frailtyscore 1.98(0.35) 2.09(0.38) −0.12(−0.74,0.50) −0.09 0.714 0.22
QualityofLifeScore 72.1(2.6) 74.7(2.8) −2.64(−6.7,1.4) −0.28 0.206 0.50
Estimatesshownareage,sex,educationandbaselinescoreadjustedforeachoutcomemeasureinseparatelinear
regressionmodels.Measuresofassociation(effectsizeandp-valuefortestofmeandifferencesbyinterventiongroup)
areshownforoverallsample(regardlessofHIV-status).Statisticallysignificantdifferencesanddifferenceswith
correspondingeffectsize>|0.30|arebolded.Giventhesmallsamplesize,weinterpretpotentialclinicalrelevance
usingacombinationofstatisticalsignificanceanddifferencesinESof|0.3|whichcorrespondstoatleastamoderate
effectperliteratureonpatient-reportedoutcomes.ESdifferencesof≤|0.2|areconsidered‘small’.#=number.
J.Clin.Med.2020,9,2137 10of15
Table4. CCRTIntervention-RelatedChangeinCognitiveandQOLoutcomesAmongOlderUgandanswithandwithoutHIVinfection.
AmongHIV-PositiveOlderUgandans AmongHIV-NegativeOlderUgandans
CCRT NoCCRT EstimatedEffect CCRT NoCCRT EstimatedEffect
LSMeans LSMeans EffectSize LSMeans LSMeans EffectSize
β(95%CI) β(95%CI)
(SE) (SE) (p-Value) (SE) (SE) (p-Value)
WHOUCLALearningTests(#Correct)
ImmediateRecall(trials1–5) 10.1(0.39) 9.2(0.43) 0.91(0.08,1.73) 0.69(0.032) 9.83(0.42) 9.9(0.43) −0.19(−0.96,0.57) −0.14(0.620)
InterferenceListRecall(trial6) 5.3(0.52) 5.3(0.59) 0.01(−1.12,1.13) 0.02(0.992) 5.6(0.57) 6.1(0.59) −0.50(−1.52,0.52) −0.29(0.334)
PostInterferenceListRecall(trial7) 10.5(0.70) 9.5(0.77) 1.03(−0.43,2.49) 0.44(0.168) 10.1(0.75) 9.1(0.76) 1.05(−0.31,2.41) 0.45(0.129)
DelayedRecall(trial8) 11.5(0.68) 10.6(0.75) 0.91(−0.49,2.30) 0.41(0.202) 11.6(0.73) 10.6(0.39) 1.00(−0.31,2.32) 0.45(0.135)
WordRecognition(trial9) 13.4(0.60) 13.7(0.26) −0.34(−1.6,0.92) −0.15(0.602) 14.0(0.66) 13.6(0.66) 0.46(−0.74,1.65) 0.20(0.451)
DigitSpanTest(#correct)
Shorttermauditorymemory/simpleattention 5.05(0.37) 5.3(0.41) −0.21(−0.97,0.56) −0.17(0.560) 4.7(0.40) 5.3(0.40) −0.54(−1.26,0.19) −0.44(0.147)
Short-termverbalmemory 4.35(0.47) 3.56(0.52) 0.79(−0.18,1.77) 0.51(0.112) 4.47(0.50) 4.26(0.51) 0.20(−0.72,1.12) 0.13(0.666)
Overallscore 9.57(0.65) 8.63(0.73) 0.95(−0.42,2.32) 0.32(0.174) 9.02(0.71) 9.63(0.71) −0.62(−1.92,0.68) −0.21(0.351)
ColorTrails(time,s) 96.6(19.0) 117(21) −20.9(−60.8,19.1) −0.32(0.306) 125(20.4) 128(20.7) −3.2(−40.1,33.7) −0.05(0.867)
FingerTappingTest(#taps) 38.2(1.6) 36.2(1.7) 2.1(−1.4,5.6) 0.38(0.233) 37.7(1.82) 37.5(1.79) 0.2(−3.1,3.5) 0.04(0.903)
GroovedPegBoard(time,s)
GroovedPegboardNDH 126.5(10.7) 125(11.6) 2.0(−20.0,24.0) 0.06(0.860) 136(11.5) 129(11.5) 6.6(−14.2,27.4) 0.20(0.535)
GroovedPegboardDH 97.9(8.6) 92.5(9.5) 5.5(−12.2,23.2) 0.20(0.542) 102.9(9.1) 91.6(9.2) 11.4(−5.0,27.7) 0.41(0.172)
VerbalFluency
VerbalFluency(Tot.Correct) 13.2(1.0) 11.5(1.03) 1.68(−0.32,3.67) 0.51(0.099) 13.5(1.04) 12.7(1.05) 0.87(−0.99,2.72) 0.26(0.358)
TimedGait(time,s) 9.5(0.97) 10.9(1.06) −1.43(−3.5,0.60) −0.44(0.167) 9.9(1.06) 9.8(1.09) 0.12(−1.8,2.0) 0.04(0.904)
SymbolDigitModality(#correct) 23.6(2.1) 26.0(2.3) −2.4(−6.8,2.0) −0.34(0.286) 25.5(2.29) 26.7(2.31) −1.24(−5.4,2.9) −0.17(0.556)
Frailtyscore 2.24(0.23) 2.22(0.26) 0.02(−0.47,0.51) 0.03(0.931) 2.29(0.26) 2.83(0.26) −0.54(−1.00,−0.08) −0.71(0.023)
QualityofLifeScore 72.9(3.2) 74.8(3.2 −1.9(−7.8,4.1) −0.20(0.533) 71.1(3.2) 73.2(3.1) −2.1(−8.0,3.9) −0.22(0.490)
Estimatesshownareage,sex,education,andbaselinescoreadjustedforeachoutcome(bolded)inseparatelinearregressionmodels.Measuresofassociation(effectsizeandp-valuefor
testofmeandifferencesbyinterventiongroup)areshownforoverallsample(regardlessofHIV-status)andwithinHIV-statusgroups.WithinHIVgroups,adjustedleast-squaremeansand
SEforrespectivetestsareshownforCCRTvs.noCCRTgroups.Statisticallysignificantdifferencesanddifferenceswithcorrespondingeffectsize>|0.30|areboldedGivensmallsample
size,weinterpretpotentialclinicalrelevanceusingacombinationofstatisticalsignificanceanddifferencesinESof|0.30|whichcorrespondstoatleastmoderateeffectperliteratureon
patientreportedoutcomes.ESdifferencesof<=|0.2|areconsidered‘small’.QOL=QualityofLife,#=Number.
J.Clin.Med.2020,9,2137 11of15
4. Discussion
Withmorethan90%ofindividualsassignedtoCCRTcompletingthestudyprotocol,andover
70% doing so within 8 weeks of enrolment, we concluded that the CCRT intervention is feasible
amongUgandanadults50yearsandabove. AlthoughoverallcompletionratewassimilarbyHIV
status,timelyprotocolcompletionwasloweramongHIV-infectedadultssuggestingthatfuturestudies
willneedtoincreaseeffortstoencouragetimelyreturnforcognitivetrainingamongHIV-infected
adultsorpotentiallydevelopmorelocaladministrationoptions. Overallfindingssuggestthepotential
utilityofCCRTformitigatingHIV-andaging-relatedneurocognitiveimpairmentinUgandanadults
50yearsandabove. Givenoursamplesizeandthefeasibilityintentofthisinvestigation,weinterpret
potentialclinicalrelevanceusingacombinationofstatisticalsignificanceanddifferencesinESof≥|0.33|,
whichcorrespondstothedifferenceofatleastmoderateclinicalimportanceasperliteratureonpatient
reportedoutcomes[30–32]. ThepotentialefficacyofCCRT-interventionreportedhereissimilarto
previousobservationsamongpatientswithearlyAlzheimer’sDisease[33].
StudyresultsshowthatregardlessofHIVstatus,olderadultswhoparticipatedinCCRTshowed
improvementsofatleastmodestclinicalimportanceintestsofexecutivefunction(verbalfluency)
and verbal learning/memory (interference list and delayed recall) relative to the control group.
Thesepreliminaryfindingsofneurocognitivebenefitsofmodestclinicalimportanceinsomecognitive
domains are consistent with previous reports of CCRT-related neurocognitive benefit in healthy
older individuals [34], older adults with HIV infection [35–38], and older individuals with mild
cognitiveimpairment[39]. Specifically,amonghealthyolderAmericans(meanage=69,SD=6.9),
CCRT targeting auditory perception and visuomotor/working memory domains of cognition was
associatedwithpost-trainingimprovementsintestsofeverydayproblemsolving,workingmemory
and matrix reasoning [34]. Our observations that CCRT improved post interference and delayed
recallinolderUgandansissimilartopreviouslyreportedcognitivetraining-relatedimprovementin
episodicrecallandrecognitioninHIV-negativeFrenchindividualswithmildcognitiveimpairment[39],
andwithimprovementintestsofprocessingspeedandtimetocompletionofinstrumentalactivities
of daily living, in a small sample of HIV-infected American adults 40 years or older [35]. Hence,
emergingdatafromthepresentstudyandothers,includingarecentmeta-analysisof12studiesin
patientswithmildcognitiveimpairmentorsubjectivecognitivedecline[40], areinsupportofthe
thesisthatCCRTinpopulationsathighriskofaging-andHIV-relatedneurocognitivedysfunction
stimulatesneuroplasticitythatcanbuildnewandstrongerconnectionsbetweenneuronsandtranslate
tomeasurableimprovementsobservedinsomeneurocognitivedomains[41]. However,notallstudies
havefoundCCRT-relatedneurocognitivebenefits,includingapreviouslyreportedobservationofno
cognitiveperformancebenefitofacomputer-basedcognitiveexerciseprogramonage-relatedcognitive
declineamongAmericanseniors[42].
WefoundmoreconsistentandbroaderneurocognitivebenefitofCCRTvs. noCCRTtrainingamong
HIV-positiveolderUgandanswithclinicallymoderateorlargecognitivelybeneficialeffectsnotedin
theareasofverballearning/memory(immediateanddelayedrecalltests),short-termworkingmemory
(digitspanbackwards),executivefunction(verbalfluency),psychomotorfunction(fingertapping,
timedgait),andprocessingspeed(i.e.,colortrails). Ofnote,atenrolment,HIV-infectedolderadultshad
abroaderscopeofneurocognitivedisadvantagerelativetodemographically-matchedHIV-negative
communitycontrolswithworseperformanceinmotorfunction(Timedgait,fingertapping,dominant
hand grooved pegboard), simple attention (digit span forward) and short-term verbal memory
(digitspanbackward)tests. Hence,alargerbenefitofCCRTinterventioninHIV-infectedolderadult
partlyreflectsthegreaterburdenofneurocognitiveimpairment(andthusopportunityforCCRT-related
remediation)inthisgroup[43,44]. ThispositionissupportedbyKauretal.’sobservationthatthe
largestpostCCRTneurocognitivebenefitintheirsampleoccurredinHIV-positiveadultsthathad
the lowest baseline neurocognitive performance, higher viral load, poorer medication adherence,
andthegreatestnumberofyearslivedwithHIVinfection[45]. Inspiteofthesehypothesesconfirming
associationbetweenCCRTandneurocognitivefunctionamongHIV-infectedadults,incontrastwith
J.Clin.Med.2020,9,2137 12of15
ourstudyhypothesis,therewasnoevidencethatCCRTinterventionwasbeneficialforqualityoflife
orFRPreductionamongolderadultslivingwithHIV.
AmongHIV-negativeolderadults,alargehypothesisconfirmingCCRT-relateddeclineinFRPwas
observedalthoughCCRTwasunrelatedtoimprovementinQOL.Infact,CCRTintervention-related
neurocognitivebenefitamongHIV-negativeolderadultswasrelativelyinconsistentandoccurred
infewercognitivedomainscomparedtoHIV-infectedpeers. TheCCRTrelatedreductioninfrailty
alignswiththeobservationthatcognitivetraininginolderpatientswithmildcognitiveimpairment
wasassociatedwithmodestimprovementsinself-ratedQOL,activitiesofdailylivingandfunctional
ability[46]. Withrespecttopost-interventioncognitivescores,theCCRT-relatedmoderateimprovement
observedinlearningandmemorytestsamongHIV-negativecommunitycontrolswasinconsistent
withmoderatelyworsescoresintestsofsimpleattentionandworseperformanceintestofhand-eye
coordination/manualdexterity(groovedpegboard)observedinthesameolderadultsthatreceived
CCRTvs. SOC.Futurestudieswithlargersamplesizewillbeneededtoclarifythesefindings.
Toourknowledge,thisisthefirstevaluationofthefeasibilityandpromiseofCCRTformitigating
agingandHIV-associatedneurocognitivedeclineandforreducingFRPinUgandanadultsover50years
old. CulturaladaptationoftheCCRTintervention,utilizationofopen-sourcetechnologyplatform,
andinclusionofHIV-positiveandHIV-negativeolderUgandansmatchedonkeydemographicfactors
areimportantstrengthsinthisfeasibilitystudy. ThefactthatCCRTandSOCarmsweresimilarat
baselinewithrespecttoseveraldemographiccovariatesandpre-testneuropsychologicalperformance,
andattritionwaslowbystudyend,areadditionalstrengths. However,thisstudyissubjecttothe
threelimitationsthatshouldbeconsideredintheinterpretationofthisstudyandinthedesignof
definitivefuturestudies: (a)CCRTinterventionwasnotrandomlyallocated,limitingourabilityto
excludeconfoundingbyunmeasuredcovariate;(b)post-testinterventiondurationwasrelativelyshort,
excludingtheabilitytotestforstabilityofobservedassociations,and(c)repeatneuropsychological
testingdidnotuseaparallelversionofrespectivetools,raisingthepotentialforlearningeffectupon
repeattesting. Theseresultsarepromisingandsuggestslargerinvestigationsarewarrantedtoformally
testtheefficacyofCCRTformitigationofprematureneurocognitivedecline,highriskoffrailtyand
lowqualityoflifeinthisvulnerablepopulation.
5. Conclusions
PreliminarydatafromthisfeasibilitystudysuggestthatCCRTmaybeapromisingnon-pharmacologic
intervention for mitigating neurocognitive decline and aging-related disability in older Africans,
especiallythosewithHIVinfection. Thesefindingsunderscoretheneedforprospectivelypowered
clinicaltrialstotesttheefficacyofthisinterventionandthecorrespondingdurationofanyCCRT-related
neuroprotective effects. If these preliminary findings are supported by more definitive studies,
thenCCRTrepresentsapotentiallyeffectiveyetaffordablestrategyformakingacommunity-wide
impactonagrowingpublichealthprobleminSSAandbeyond.
Author Contributions: Conceptualization, B.G., M.J.B.; formal analysis, A.E.E., A.S.; data curation, A.E.E.;
writing—originaldraftpreparation,A.E.E.,P.R.S.,A.S.;writing—reviewandediting,A.E.E.,P.R.S.,A.S.,B.G.,
D.G.,M.S.,M.J.B.,N.E.K.;projectadministration,M.S.;N.N.,D.G.,A.E.E.,B.G.;fundingacquisition,A.E.E.,M.J.B.
Allauthorshavereadandagreedtothepublishedversionofthemanuscript.
Funding: ResearchsupportfordatacollectionwasprovidedthroughtheDepartmentofPsychiatry,Collegeof
OsteopathicMedicine,MichiganStateUniversity,EastLansing,MI,USA.Additionalresourcesforprofessional
developmentwasprovidedbytheMichiganAlzheimer’sDiseaseResearchCenter(P30AG053760).
Acknowledgments: Weacknowledgewiththanksthekindindulgenceofstudyparticipants,thediligenceof
ourfieldresearchstaff—MonicaLyagobaOkumbe,IvanFelixByonna,NyangomaBettyOpio,EthelNuamanya
Wandeka,TitusSessanga,RichardSevviiri,andFaithKaddu;andadministrativesupportbyRobertTuke.
ConflictsofInterest: Theauthorsdeclarenoconflictofinterest. Thefundershadnoroleinthedesignofthe
study;inthecollection,analyses,orinterpretationofdata;inthewritingofthemanuscript,orinthedecisionto
publishtheresults.
J.Clin.Med.2020,9,2137 13of15
References
1. Hayutin,A.M.GrayingoftheGlobalPopulation. PublicPolicyAgingRep. 2007,17,12–17. [CrossRef]
2. Walker, J.M.; Harrison, F.E. Shared Neuropathological Characteristics of Obesity, Type 2 Diabetes and
Alzheimer’sDisease: ImpactsonCognitiveDecline. Nutrients2015,7,7332–7357. [CrossRef][PubMed]
3. Glahn, D.C.; Kent, J.; Sprooten, E.; Diego, V.; Winkler, A.M.; Curran, J.E.; McKay, D.R.; Knowles, E.E.;
Carless,M.A.;Göring,H.H.H.;etal. Geneticbasisofneurocognitivedeclineandreducedwhite-matter
integrityinnormalhumanbrainaging. Proc. Natl. Acad. Sci. USA2013,110,19006–19011. [CrossRef]
[PubMed]
4. Chang,H.;Hawley,N.L.;Kalyesubula,R.;Siddharthan,T.;Checkley,W.;Knauf,F.;Rabin,T.Challengesto
hypertensionanddiabetesmanagementinruralUganda: Aqualitativestudywithpatients,villagehealth
teammembers,andhealthcareprofessionals. Int. J.EquityHealth2019,18,38. [CrossRef]
5. Brands,A.M.; Berg,E.V.D.; Manschot,S.M.; Biessels,G.J.; Kappelle,L.J.; DeHaan,E.H.; Kessels,R.P.C.
Adetailedprofileofcognitivedysfunctionanditsrelationtopsychologicaldistressinpatientswithtype2
diabetesmellitus. J.Int. Neuropsychol. Soc. 2007,13,288–297. [CrossRef][PubMed]
6. Gottesman,R.F.;Schneider,A.L.;Albert,M.;Alonso,A.;Bandeen-Roche,K.;Coker,L.;Coresh,J.;Knopman,D.;
Power,M.C.;Rawlings,A.M.;etal. Midlifehypertensionand20-yearcognitivechange: Theatherosclerosis
riskincommunitiesneurocognitivestudy. JAMANeurol. 2014,71,1218–1227. [CrossRef]
7. DeRoos,A.;VanDerGrond,J.;Mitchell,G.;Westenberg,J.MagneticResonanceImagingofCardiovascular
FunctionandtheBrain: IsDementiaaCardiovascular-DrivenDisease? Circulation2017,135,2178–2195.
[CrossRef]
8. Grady,C.L.Thecognitiveneuroscienceofageing. Nat. Rev. Neurosci. 2012,13,491–505. [CrossRef]
9. Stern, A.L.; Ghura, S.; Gannon, P.J.; Akay-Espinoza, C.; Phan, J.; Yee, A.; Vassar, R.; Gelman, B.B.;
Kolson, D.L.; Jordan-Sciutto, K.L. BACE1 Mediates HIV-Associated and Excitotoxic Neuronal Damage
throughanAPP-DependentMechanism. J.Neurosci. 2018,38,4288–4300. [CrossRef]
10. Becker, J.T.; Dew, M.A.; Aizenstein, H.J.; Lopez, O.L.; Morrow, L.; Saxton, J.; Tárraga, L. A pilot study
of the effects of internet-based cognitive stimulation on neuropsychological function in HIV disease.
Disabil.Rehabilit. 2012,34,1848–1852. [CrossRef]
11. Vance, D.E.; Fazeli, P.L.; Gakumo, C.A. The impact of neuropsychological performance on everyday
functioningbetweenolderandyoungeradultswithandwithoutHIV.J.Assoc. NursesAIDSCare2012,24,
112–125. [CrossRef][PubMed]
12. Malkasian,D.R.;Diamond,M.C.TheEffectsofEnvironmentalManipulationOnTheMorphologyofThe
NeonateRatBrain. Int. J.Neurosci. 1971,2,161–169. [CrossRef]
13. Marusic,U.;Giordani,B.;Moffat,S.D.;Petricˇ,M.;Dolenc,P.;Pišot,R.;Kavcic,V.Computerizedcognitive
trainingduringphysicalinactivityimprovesexecutivefunctioninginolderadults. AgingNeuropsychol. Cogn.
2016,25,49–69. [CrossRef]
14. Marusic,U.;Kavcic,V.;Giordani,B.;Gerževicˇ,M.;Meeusen,R.;Pišot,R.Computerizedspatialnavigation
trainingduring14daysofbedrestinhealthyolderadultmen: Effectongaitperformance. Psychol. Aging
2015,30,334–340. [CrossRef][PubMed]
15. Hempel,A.;Schröder,J.;Caraballo,N.M.G.;Giesel,F.L.;Amann,M.;Meyer,H.;Wüstenberg,T.;Essig,M.
PlasticityofCorticalActivationRelatedtoWorkingMemoryduringTraining. Am. J.Psychiatry2004,161,
745–747. [CrossRef][PubMed]
16. Klingberg,T.Trainingandplasticityofworkingmemory. TrendsCogn. Sci. 2010,14,317–324. [CrossRef]
17. Nikolaidis,A.;Voss,M.W.;Lee,H.;Vo,L.T.K.;Kramer,A.F.Parietalplasticityaftertrainingwithacomplex
videogameisassociatedwithindividualdifferencesinimprovementsinanuntrainedworkingmemory
task. Front. Hum. Neurosci. 2014,8,169. [CrossRef][PubMed]
18. Boivin, M.J.; Nakasujja, N.; Sikorskii, A.; Opoka, R.O.; Giordani, B. A Randomized Controlled Trial to
EvaluateifComputerizedCognitiveRehabilitationImprovesNeurocognitioninUgandanChildrenwith
HIV.AIDSRes. Hum. Retrovir. 2016,32,743–755. [CrossRef][PubMed]
19. Boivin,M.J.;Busman,R.A.;Parikh,S.M.;Bangirana,P.;Page,C.;Opoka,R.O.;Giordani,B.Apilotstudyof
theneuropsychologicalbenefitsofcomputerizedcognitiverehabilitationinUgandanchildrenwithHIV.
Neuropsychology2010,24,667–673. [CrossRef]
J.Clin.Med.2020,9,2137 14of15
20. Bangirana,P.;Giordani,B.;John,C.C.;Page,C.;Opoka,R.O.;Boivin,M.J.ImmediateNeuropsychological
andBehavioralBenefitsofComputerizedCognitiveRehabilitationinUgandanPediatricCerebralMalaria
Survivors. J.Dev. Behav. Pediatr. 2009,30,310–318. [CrossRef]
21. Bangirana,P.;Allebeck,P.;Boivin,M.J.;John,C.C.;Page,C.;Ehnvall,A.;Musisi,S.Cognition,behaviourand
academicskillsaftercognitiverehabilitationinUgandanchildrensurvivingseveremalaria: Arandomised
trial. BMCNeurol. 2011,11,96. [CrossRef][PubMed]
22. Willis, S.L.; Tennstedt, S.L.; Marsiske, M.; Ball, K.; Elias, J.; Koepke, K.M.; Morris, J.N.; Rebok, G.W.;
Unverzagt,F.W.;Stoddard,A.M.;etal. Long-termEffectsofCognitiveTrainingonEverydayFunctional
OutcomesinOlderAdults. JAMA2006,296,2805–2814. [CrossRef][PubMed]
23. Pressler,S.J.;Titler,M.;Koelling,T.M.;Riley,P.L.;Jung,M.;Hoyland-Domenico,L.;Ronis,D.L.;Smith,D.G.;
Bleske, B.E.; Dorsey, S.G.; et al. Nurse-Enhanced Computerized Cognitive Training Increases Serum
Brain-DerivedNeurotropicFactorLevelsandImprovesWorkingMemoryinHeartFailure. J.Card. Fail.
2015,21,630–641. [CrossRef][PubMed]
24. Pressler,S.J.;Therrien,B.;Riley,P.L.;Chou,C.-C.;Ronis,D.L.;Koelling,T.M.;Smith,D.G.;Sullivan,B.J.;
Frankini,A.-M.;Giordani,B.Nurse-EnhancedMemoryInterventioninHeartFailure: TheMEMOIRStudy.
J.Card. Fail. 2011,17,832–843. [CrossRef]
25. Schein,R.L.;Koenig,H.G.TheCenterforEpidemiologicalStudies-Depression(CES-D)Scale: Assessmentof
depressioninthemedicallyillelderly. Int. J.Geriatr. Psychiatry1997,12,436–446. [CrossRef]
26. Glover,D.A.;Garcia-Aracena,E.F.;Lester,P.;Rice,E.;Rothram-Borus,M.J.StressBiomarkersasOutcomes
forHIV+Prevention: Participation,FeasibilityandFindingsamongHIV+LatinaandAfricanAmerican
Mothers. AIDSBehav. 2009,14,339–350. [CrossRef]
27. Nakasujja,N.;Skolasky,R.L.;Musisi,S.;Allebeck,P.;Robertson,K.R.;Ronald,A.R.;Katabira,E.;Clifford,D.B.;
Sacktor,N.DepressionsymptomsandcognitivefunctionamongindividualswithadvancedHIVinfection
initiatingHAARTinUganda. BMCPsychiatry2010,10,44. [CrossRef]
28. Norman,G.;Sloan,J.A.;Wyrwich,K.W.InterpretationofChangesinHealth-relatedQualityofLife. Med.Care
2003,41,582–592. [CrossRef]
29. Erder,M.H.;Santanello,N.;Hays,R.D.Assessingtheclinicalsignificanceofpatient-reportedoutcomes:
Examplesdrawnfromarecentmeetingofthedruginformationassociation(DIA).Clin. Ther. 2003,25,
D12–D13. [CrossRef]
30. Norman, G.R.; Sloan, J.A.; Wyrwich, K.W. Interpretation of changes in health-related quality of
life—Theremarkableuniversalityofhalfastandarddeviation. Med. Care2003,41,582–592. [CrossRef]
31. Rothrock,N.E.;Hays,R.D.;Spritzer,K.;Yount,S.E.;Riley,W.;Cella,D.RelativetothegeneralUSpopulation,
chronicdiseasesareassociatedwithpoorerhealth-relatedqualityoflifeasmeasuredbythePatient-Reported
OutcomesMeasurementInformationSystem(PROMIS).J.Clin. Epidemiol. 2010,63,1195–1204. [CrossRef]
[PubMed]
32. Cella,D.;Eton,D.;Fairclough,D.;Bonomi,P.;Heyes,A.;Silberman,C.;Wolf,M.;Johnson,D.Whatisa
clinicallymeaningfulchangeontheFunctionalAssessmentofCancerTherapy–Lung(FACT-L)Questionnaire?
ResultsfromEasternCooperativeOncologyGroup(ECOG)Study5592. J.Clin. Epidemiol. 2002,55,285–295.
[CrossRef]
33. Cavallo,M.;Hunter,E.M.;vanderHiele,K.;Angilletta,C.ComputerizedStructuredCognitiveTrainingin
PatientsAffectedbyEarly-StageAlzheimer’sDiseaseisFeasibleandEffective: ARandomizedControlled
Study. Arch. Clin. Neuropsychol. 2016,31,868–876. [CrossRef][PubMed]
34. Strenziok,M.;Parasuraman,R.;Clarke,E.;Cisler,D.S.;Thompson,J.C.;Greenwood,P.M.Neurocognitive
enhancementinolderadults: Comparisonofthreecognitivetrainingtaskstotestahypothesisoftraining
transferinbrainconnectivity. NeuroImage2014,85,1027–1039. [CrossRef]
35. Cody,S.L.;Fazeli,P.L.;Vance,D.E.FeasibilityofaHome-BasedSpeedofProcessingTrainingProgramin
Middle-AgedandOlderAdultswithHIV.J.Neurosci. Nurs. 2015,47,247–254. [CrossRef]
36. Ownby, R.; Acevedo, A. A pilot study of cognitive training with and without transcranial direct
current stimulation to improve cognition in older persons with HIV-related cognitive impairment.
Neuropsychiatr.Dis.Treat. 2016,12,2745–2754. [CrossRef]
37. Towe,S.L.;Patel,P.;Meade,C.S.TheAcceptabilityandPotentialUtilityofCognitiveTrainingtoImprove
WorkingMemoryinPersonsLivingwithHIV:APreliminaryRandomizedTrial. J.Assoc. NursesAIDSCare
2017,28,633–643. [CrossRef][PubMed]
J.Clin.Med.2020,9,2137 15of15
38. Vance,D.E.;Jensen,M.;Tende,F.;Raper,J.L.;Morrison,S.;Fazeli,P.L.Individualized-TargetedComputerized
CognitiveTrainingtoTreatHIV-AssociatedNeurocognitiveDisorder: AnInterimDescriptiveAnalysis.
J.Assoc. NursesAIDSCare2018,29,604–611. [CrossRef]
39. Herrera,C.;Chambon,C.;Michel,B.F.;Paban,V.;Alescio-Lautier,B.Positiveeffectsofcomputer-based
cognitivetraininginadultswithmildcognitiveimpairment. Neuropsychologia2012,50,1871–1881. [CrossRef]
40. Hu,M.;Wu,X.;Shu,X.;Hu,H.;Chen,Q.;Peng,L.;Feng,H.Effectsofcomputerisedcognitivetrainingon
cognitiveimpairment: Ameta-analysis. J.Neurol. 2019,1–9. [CrossRef]
41. Hardy,D.J.;Vance,D.E.TheNeuropsychologyofHIV/AIDSinOlderAdults. Neuropsychol. Rev. 2009,19,
263–272. [CrossRef][PubMed]
42. Bozoki,A.C.;Radovanovic´,M.;Winn,B.;Heeter,C.;Anthony,J.C.Effectsofacomputer-basedcognitive
exerciseprogramonage-relatedcognitivedecline. Arch. Gerontol. Geriatr. 2013,57,1–7. [CrossRef][PubMed]
43. Ciccarelli,N.;Fabbiani,M.;Baldonero,E.;Fanti,I.;Cauda,R.;DiGiambenedetto,S.;Silveri,M.C.Effectof
AgingandHumanImmunodeficiencyVirusInfectiononCognitiveAbilities. J.Am. Geriatr. Soc. 2012,60,
2048–2055. [CrossRef][PubMed]
44. Vance,D.E.;Fazeli,P.L.;Ross,L.A.;Wadley,V.G.;Ball,K.SpeedofProcessingTrainingwithMiddle-Ageand
OlderAdultswithHIV:APilotStudy. J.Assoc. NursesAIDSCare2012,23,500–510. [CrossRef]
45. Kaur,J.;Dodson,J.E.;Steadman,L.;Vance,D.E.PredictorsofImprovementFollowingSpeedofProcessing
TraininginMiddle-AgedandOlderAdultswithHIV.J.Neurosci. Nurs. 2014,46,23–33. [CrossRef]
46. Li, H.; Li, J.; Li, N.; Li, B.; Wang, P.; Zhou, T. Cognitive intervention for persons with mild cognitive
impairment: Ameta-analysis. AgeingRes. Rev. 2011,10,285–296. [CrossRef]
©2020bytheauthors. LicenseeMDPI,Basel,Switzerland. Thisarticleisanopenaccess
articledistributedunderthetermsandconditionsoftheCreativeCommonsAttribution
(CCBY)license(http://creativecommons.org/licenses/by/4.0/).
